within Pharmacolibrary.Drugs.ATC.L;

model L01FY01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.003916666666666666,
    adminDuration  = 600,
    adminMass      = 0.84,
    adminCount     = 1,
    Vd             = 0.0031,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Pertuzumab and trastuzumab are monoclonal antibody drugs used in combination for the treatment of HER2-positive breast cancer. They bind to different epitopes of the HER2 receptor, providing dual blockade and thereby improving clinical outcomes. This combination is approved and widely used in clinical practice for the treatment of HER2-positive metastatic breast cancer, early breast cancer, and in some neoadjuvant settings.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters reported in adult female patients with HER2-positive breast cancer receiving intravenous pertuzumab and trastuzumab, typically with chemotherapy.</p><h4>References</h4><ol><li>Antoinette R Tan, Seock-Ah Im, Andr√© Mattar, Ramon Colomer, Daniil Stroyakovskii, Zbigniew Nowecki, Michelino De Laurentiis, Jean-Yves Pierga, Kyung Hae Jung, Christian Schem, Alexandra Hogea, Tanja Badovinac Crnjevic, Sarah Heeson, Mahesh Shivhare, Whitney P Kirschbrown, Eleonora Restuccia, Christian Jackisch,Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.,The Lancet. Oncology,2021<a href='https://pubmed.ncbi.nlm.nih.gov/33357420/'>https://pubmed.ncbi.nlm.nih.gov/33357420/</a></li><li>Andrea Rocca, Daniele Andreis, Anna Fedeli, Roberta Maltoni, Samanta Sarti, Lorenzo Cecconetto, Elisabetta Pietri, Alessio Schirone, Sara Bravaccini, Patrizia Serra, Alberto Farolfi, Dino Amadori,Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.,Expert opinion on drug metabolism & toxicology,2015<a href='https://pubmed.ncbi.nlm.nih.gov/26307328/'>https://pubmed.ncbi.nlm.nih.gov/26307328/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01FY01;
